Goldman Sachs analyst David Roman maintained a Buy rating on GE Healthcare Technologies Inc (GEHC – Research Report) yesterday and set a price target of $85.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
David Roman’s rating is based on several positive indicators for GE Healthcare Technologies Inc. The company is experiencing a strong U.S. hospital capital expenditure environment, which has not shown any signs of weakness despite potential policy-related challenges. This robust environment, particularly in cardiology and imaging specialties, is driving new order growth, supported by improvements in EMEA and stabilization in China.
Additionally, GE Healthcare’s management is taking a cautious yet optimistic approach to their 2025 guidance, with expectations of 2-3% organic revenue growth for the full year. This guidance reflects a conservative outlook considering macroeconomic risks but also acknowledges the potential for upside in sales and earnings per share due to favorable market conditions and possible tariff relief. The improvement in GE Healthcare’s China business further supports the positive outlook, contributing to the overall confidence in the company’s future performance.
Roman covers the Healthcare sector, focusing on stocks such as Healthequity, GE Healthcare Technologies Inc, and Kestra Medical Technologies Ltd.. According to TipRanks, Roman has an average return of 3.1% and a 52.50% success rate on recommended stocks.